Cipla Limited

Report azionario NSEI:CIPLA

Capitalizzazione di mercato: ₹1.1t

Cipla Gestione

Criteri Gestione verificati 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Achin Gupta

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEOless than a year
Proprietà del CEOn/a
Durata media del management1.1yrs
Durata media del Consiglio di amministrazione2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Aggiornamento della narrazione • Jun 05

CIPLA: Fair Outlook As New CEO And Respiratory Portfolio Changes Take Shape

Analysts have raised their price target on Cipla by about ₹30 to ₹1,459.57, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple, alongside a marginally higher discount rate. What's in the News Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases like COPD and asthma.
Articolo di analisi • May 16

Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next

Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...
Aggiornamento della narrazione • Apr 27

CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook

Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.
Aggiornamento della narrazione • Apr 12

CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook

Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).
Aggiornamento della narrazione • Mar 27

CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook

Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).
Aggiornamento della narrazione • Mar 13

CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook

Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).
Aggiornamento della narrazione • Feb 27

CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook

Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).
Aggiornamento della narrazione • Feb 13

CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations

Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).
Aggiornamento della narrazione • Jan 30

CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential

Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).
Articolo di analisi • Jan 28

Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next

The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...
Articolo di analisi • Jan 17

The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet

With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...
Aggiornamento della narrazione • Jan 16

CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential

Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Articolo di analisi • Dec 29

We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Articolo di analisi • Nov 20

Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Articolo di analisi • Nov 02

Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...
Articolo di analisi • Sep 24

Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares

With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...
Articolo di analisi • Sep 06

Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Aggiornamento della narrazione • Sep 04

Emerging Markets And Chronic Therapies Will Open New Horizons

With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.
Articolo di analisi • Jul 13

Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
User avatar
Nuova narrazione • Nov 10

Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions

Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.

AMMINISTRATORE DELEGATO

Achin Gupta (50 yo)

less than a year
Mandato

Mr. Achin Gupta serves as Managing Director, Global Chief Executive Officer and Director of Cipla Limited since April 01, 2026. He served as Chief Executive Officer of One India Business at Cipla Limited s...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Achin Gupta
MD, Global CEO & Directorless than a yearNessun datoNessun dato
Sushrut Kulkarni
President & Global Chief Integrated Product Developmentless than a yearNessun datoNessun dato
Ashish Adukia
Global Chief Financial Officer3.8yrsNessun datoNessun dato
Dinesh Jain
Senior VP & Head of Corporate Financeno dataNessun datoNessun dato
Sneha Hiranandani
Global Chief Information Officer1.9yrsNessun datoNessun dato
Diksha Maheshwari
Head of Investor Relationsno dataNessun datoNessun dato
Rajendra Chopra
Compliance Officer & Company Secretary9.3yrs₹15.30mNessun dato
Meera Vanjari
Global Chief General Counselless than a yearNessun datoNessun dato
Heena Kanal
Chief of Corporate Communicationno dataNessun datoNessun dato
Arun Kakatkar
Global Chief People Officerless than a yearNessun datoNessun dato
Jaideep Gogtay
Global Chief Medical Officer1.9yrsNessun datoNessun dato
Anurag Mishra
Head of Cipla Foundationno dataNessun datoNessun dato
1.1yrs
Durata media
56yo
Età media

Gestione esperta: Il team dirigenziale di CIPLA non è considerato esperto (durata media 1.1 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Achin Gupta
MD, Global CEO & Directorless than a yearNessun datoNessun dato
Yusuf Hamied
Non-Executive Chairman53.9yrs₹25.80m18.63%
₹ 209.1b
Adil Zainulbhai
Non Executive Director11.9yrs₹26.50mNessun dato
Kamil Hamied
Non-Executive Director1.6yrs₹26.30m1.35%
₹ 15.2b
Sharmila Paranjpe
Independent Director1.8yrs₹9.80mNessun dato
Maya Hari
Independent Director1.6yrs₹11.00mNessun dato
Mandar Vaidya
Independent Director3.9yrs₹9.30mNessun dato
Prathivadibhayankara Ramesh
Independent Vice-Chairman & Lead Independent Director4.9yrs₹11.00mNessun dato
Balram Bhargava
Independent Director2.2yrs₹9.20mNessun dato
Abhijit Joshi
Non-Executive Non Independent Director1.8yrs₹25.90mNessun dato
2.0yrs
Durata media
65yo
Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CIPLA non è considerato esperto (durata media del mandato 2 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/15 14:08
Prezzo dell'azione a fine giornata2026/06/15 00:00
Utili2026/03/31
Utili annuali2026/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Cipla Limited è coperta da 55 analisti. 36 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Rohit Bhat360 ONE Capital Market Private Limited
Gaurav TinaniAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited